An expanded access program to investigate the combination of lumacaftor and ivacaftor in patients with severe lung disease

Trial Profile

An expanded access program to investigate the combination of lumacaftor and ivacaftor in patients with severe lung disease

Planning
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 07 Nov 2014

At a glance

  • Drugs Ivacaftor (Primary) ; Ivacaftor/lumacaftor (Primary) ; Lumacaftor (Primary)
  • Indications Cystic fibrosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Nov 2014 New trial record
    • 05 Nov 2014 According to a Vertex Pharmaceuticals media release, the company plans to begin this trial for a limited number of people in the second quarter of 2015, pending discussion with the FDA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top